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1.71) or re-admission (HR: 0.89, 95% CI: 0.78-1.02). CONCLUSIONS: The higher risk 
of severe hypoglycemic events and re-admission associated with non-PI-
concordant OAD treatment after being discharged among hospitalized T2DM 
patients with moderate to severe CKD suggests prescribing patterns that 




ORAL ANTIDIABETIC USE AMONG NURSING HOME RESIDENTS WITH DIABETES 
AND MODERATE TO SEVERE CHRONIC KIDNEY DISEASE  
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OBJECTIVES: To assess the rate of non-concordant use of oral anti-diabetic drugs 
(OAD) according to National Kidney Foundation (NKF) guidelines and drug 
package inserts (PI) among nursing home (NH) residents with diabetes and 
moderate to severe chronic kidney disease (CKD). METHODS: Long-term care 
administrative database with medical and pharmacy claims information was 
analyzed. Residents with diabetes and moderate to severe CKD who remained in 
NHs for at least 90 consecutive days between 2008 and 2011 were selected. 
Residents with moderate to severe CKD was identifed if they had at least one 
glomerular filtration rate <60 ml/min/1.73m2in the 1 year prior to or during the 
90-day period. Concordance was analyzed among residents that filled at least 1 
prescription for OAD during the first 90-day continuous stay. If at least 1 of the 
OADs prescribed was not concordant to NKF or PIs, then that resident was 
classified as non-concordant. RESULTS: Of the 730 diabetic residents with 
diabetes and stage 3-5 CKD, 186 residents used the OADs included in the NKF 
guidelines during their 90-day stay in a NH. Of the 186 residents, 135 (72.6%) 
received the OADs in accordance with NKF guidelines, and 77 (41.4%) received 
the medications in accordance with their respective PIs. There was no significant 
difference in the age, gender, and educational status and NH facility location 
distribution among NKF and PIs concordant and non-concordant groups. 
However, residents in NKF concordant group were more likely to be Hispanic 
(32.6 vs. 13.7%, p<0.05) compared to NKF non-concordant group. CONCLUSIONS: 
The findings suggest that significant proportion of the OAD-treated residents 
with moderate to severe CKD, received at least one OAD prescription that was 
not concordant to NKF guidelines or PIs. Efforts should be made to more closely 
monitor OAD treatments of NH residents  
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ADHERENCE TO ADA HBA1C TESTING FREQUENCY AND ANTIDIABETIC 
THERAPY GUIDELINES IMPROVES PATIENT OUTCOMES  
Lian J, Liang Y 
Novo Nordisk Inc., Princeton, NJ, USA  
OBJECTIVES: The aim of this retrospective study is to evaluate the adherence of 
type 2 diabetes (T2DM) patients starting drug treatment to the ADA guidelines on 
HbA1Ctesting and treatment modification and determine its impact on treatment 
outcomes. METHODS: Data was obtained from a large health care plan claims 
database between July-2008 to December-2011. Eligible patients were aged ≥18 
years with ≥2 T2DM diagnoses (ICD-9CM codes 250.x0, 250.x2), and were drug-
naïve for ≥6 months before the first antidiabetic drug (termed “index treatment”) 
was required. Patient adherence to the HbA1C testing guideline was defined as an 
initial HbA1C test within 105 days of the index treatment and subsequent tests 
within 105 or 195 days of the previous test depending on the result (≥7 or <7%, 
respectively). Adherence to the drug modification guideline was defined as a 
change in treatment within 45 days of HbA1C ≥7%. Patient outcome after one year 
was evaluated using the HbA1Cvalues closest to 365 days after index treatment. 
RESULTS: Of the 14,164 patients who met the study criteria, 4,419(31.20%) met 
the testing criteria for drug modification (HbA1C ≥7%). Of these patients, 
546(12.36%) met the recommended testing frequency, 934(21.14%) adhered to the 
drug modification guidelines, and 117(2.65%) met both guidelines. The odds ratio 
of a patient achieving the HbA1C target (<7%) who adhered to the testing 
guideline was 4.66 compared with a patient who did not meet the testing 
guideline. Furthermore, the odds ratio of a patient in this population achieving 
the HbA1C target was 4.95 when both guidelines were met, as compared with a 
patient who met neither guideline. CONCLUSIONS: Adherence to ADA guidelines 
on HbA1C testing frequency and therapy modification correlated with improved 
outcomes one year after initial drug treatment.  
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RELATIONSHIP BETWEEN SELF-MONITORING OF BLOOD GLUCOSE  
AND TREATMENT PROGRESSION IN PATIENTS WITH TYPE 2 DIABETES 
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OBJECTIVES: To evaluate the relationship between self-monitoring of blood 
glucose (SMBG) test strip utilization and medication intensification in Type 2 
diabetes mellitus (T2DM). METHODS: A retrospective study of Marketscan data 
examined patients with T2DM with ≥2 prescription claims or a 90-day supply of 
at least one non-insulin antihyperglycemic (AH) agent during a 4-month baseline 
period between July 1, 2006 to December, 31, 2009. The first claim for an AH was 
the index date. Patients were classified by number and dosage of AH agents, and 
by their utilization of SMBG test strips during the baseline period. Utilization of 
AH agents and insulin was assessed during follow-up between months 6-12 post-
index. Medication intensification included an increase between baseline and 
follow-up in the number of AH classes used, an increase in dose, or the addition 
of insulin. An analysis of medication intensification from baseline to follow-up 
between users and non-users of SMBG test strips at baseline was conducted 
using chi-square analysis. RESULTS: Among 824,461 patients selected, 482,854 
used one, 258,477 used two, and 83,130 used three AH agents at baseline. SMBG 
test strip use was observed in 28.3% of the entire population, with 17.0% using >4 
test strips weekly. The following treatment changes occurred from baseline to 
follow-up: no change 67.9%, a decrease in AH classes 13.0%, an increase in AH 
classes 15.4%, initiating insulin 2.5%, and increasing dose 6.8%. The utilization of 
SMBG test strips at baseline in patients with no change or a decrease in 
medication intensification during follow-up was 28.0%, which was significantly 
different compared to SMBG use in patients with an increase in AH classes 
(29.1%), patients initiating insulin (32.8%), and in patients increasing dose (30.6%) 
(all P<0.001). CONCLUSIONS: The use of SMBG test strips is associated with 
medication intensification among users of AH therapy in T2DM.  
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UTILIZATION TRENDS OF VARIOUS FORMULATIONS OF TESTOSTERONE: AN 
ANALYSIS OF THE RAMQ DATABASE  
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OBJECTIVES: Testosterone is mainly used as androgen replacement therapy. The 
purpose of this study was to describe utilization trends of various testosterone 
formulations in a real life setting, using the RAMQ database. METHODS: Male 
patients covered by the Quebec provincial drug reimbursement program (RAMQ) 
who had used at least one formulation of testosterone in the period from June 1, 
2003 to March 31, 2011 were selected. Characteristics of the treatments were 
analyzed, including switches from one formulation to another. A 1:1 control 
group matched for age of patients not using any formulation of testosterone was 
created and incidence of co-morbidities in patients in the study group was 
compared to the control group. RESULTS: Among a random sample of 125,000 
patients covered by the drug plan, 723 males used at least one formulation of 
testosterone (0.57%). The average age was 57.2 years (SD=14.4). A total of 7 
different formulations of testosterone were used by these patients. The most 
frequent formulations used during the study period were Andriol® (48.4%) and 
Androgel® (41.4%). Testosterone formulations were mainly prescribed by GPs 
(73%), endocrinologists (11.9%) and urologists (7.5%). About 32% of patients used 
more than one formulation during the study period. Among patients who 
switched from one formulation to another, switching to Androgel was the most 
frequent trend. Average treatment persistence varied from 147 days with 
Testim® to 674 days with Androgel. Prevalence of many co-morbidities was 
significantly higher amongst these patients compared to the control group. Co-
morbidities included mental disorders (63.2%), hyperlipidemia (63.8%), 
hypertension (51.2%), articulation pain (32.1%) back pain (31.4%), HIV (6.2%) and 
migraine (6.6%). CONCLUSIONS: Patients on androgen replacement therapy have 
significantly more co-morbidities than controls. A significant proportion of 
patients will switch to a different formulation of testosterone over time, 
Androgel being the most frequent choice.  
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THERAPEUTIC TRIAL OF INTRALESIONAL INJECTION OF MYCOPHENOLATE 
MOFETIL IN PSORIASIS VULGARIS: CLINICAL, HISTOPATHOLOGICAL AND 
IMMUNOHISTOCHEMICAL EVALUATION  
Ashoush NN 
British University in Egypt, Cairo, Egypt  
OBJECTIVES: Systemically administered mycophenolate mofetil (MMF) has a 
beneficial effect in psoriasis patients. The purpose of the current study was to 
investigate the efficacy and safety of intralesional MMF in ordinary psoriasis 
vulgaris and to find out the best regimen of treatment. METHODS: In hundred 
plaque psoriasis patients, response to different concentrations (3.125, 6.25, 12.5 
and 25 mg/ml) of MMF have been objectively evaluated and compared to control 
(5% dextrose). Patients were divided into two groups, group (A): patients who 
were injected once every two weeks for six weeks and group (B): patients who 
were injected once every week for six weeks. Patients were followed up 
clinically, histopathologically, and immunohisto-chemically for CD3. RESULTS: 
Maximum response to MMF was achieved 8 weeks after initiation of therapy. 
There was significant reduction of erythema, thickness, scaliness (P≤0.01) but not 
surface area (P=0.152) compared to control. Histopathologically, there was 
significant reduction in scores of parakeratosis, acanthosis, dilatation of 
papillary vessels and density of dermal mononuclear infiltrate. 
Immunohistochemical semi-quantitative analysis revealed variable, but in 
general, obvious degree of reduction in the density of CD3+ cellular infiltrate (i.e. 
T-cells) at the eighth visit compared to the first visit in all specimens examined. 
No significant difference could be seen in the efficacy of different concentrations 
with different regimens. No systemic or local adverse effects were noted  
apart from mild and transient burning sensation especially with higher 
concentrations. CONCLUSIONS: Intralesional MMF could be adopted as a  
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OBJECTIVES: Clinical trials have shown that ranibizumab is efficacious in 
improving vision among patients with AMD. The objectives of this study are to: 
1) evaluate whether as needed (PRN) is as effective as monthly treatment; and 
2)compare the efficacy of ranibizumab 0.5mg treatment with: a)control; 
b)ranibizumab 0.3mg; and c)bevacizumab. METHODS: This is a systematic meta-
analysis review of 8 randomized controlled clinical phase III or IV trials with a 
minimum of one year follow-up that investigated the efficacy of ranibizumab in 
treating AMD. The dependent variables were effect sizes of visual acuity gained 
and odds ratios of percentage of patients who gained ≥15 visual acuity letters. 
Weighted multiple regression analyses were used to compare the monthly 
versus PRN treatment. RESULTS: Regression results showed no significant 
differences in efficacy between PRN and monthly treatment. The ranibizumab to 
control (placebo injection/surgery) comparison (4 effect sizes, 4 odds ratios, 
N=1047): showed that ranibizumab had significantly higher improvement in 
visual acuity (g=1.20, z=7.83, p<0.05) and a higher proportion of patients who 
gained ≥15 letters (OR: 6.37; 95% CI 3.96-9.98; p<0.05). When comparing 
ranibizumab dose (6 effect sizes, 5 odds ratios, N=3449): ranibizumab 0.5mg 
showed significantly higher improvement in letters gained (g=0.08, z=2.34, 
p<0.05) than ranibizumab 0.3mg. However, the proportion of patients who gained 
≥15 letters was not significantly different. The ranibizumab to bevacizumab 
comparison (3 effect sizes, 3 odds ratios, N= 800) revealed no significant 
differences. CONCLUSIONS: Ranibizumab 0.5mg was found to be more effective 
than control and ranibizumab 0.3mg. Monthly treatment was not significantly 
different from PRN. More clinical trials are needed to compare the efficacy of 
ranibizumab and bevacizumab.  
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OBJECTIVES: To investigate the burden and epidemiology of glaucoma in a large 
health maintenance organization (HMO) in Israel. METHODS: A retrospective 
cohort study, conducted using the electronic medical databases of Maccabi 
Healthcare Services (MHS), a 2 million member HMO in Israel. The study 
population consisted of all patients who were newly diagnosed with glaucoma 
between 2003 and 2010 at MHS. In addition, for prevalence calculation we 
included all patients who are currently (2012) active members of MHS. Collected 
data included personal characteristic, relevant surgical procedures, anti-
glaucoma medications, caregiver characteristics, comorbidity, possible 
complications (asthma, depression, cardiovascular diseases, cataract) and all-
cause mortality. We investigated the age- and sex-specific prevalence and 
incidence rates, and compared the medical comorbidity and mortality of 
glaucoma patients to the general HMO population. RESULTS: A total of 26,196 
prevalent glaucoma patients aged 40 or above were identified among active 
members of MHS in 2012 with an average prevalence of 35 per 1000. Prevalence 
was strongly associated with increasing age, ranging from 7 cases per 1000 at age 
45-50 to 212 per 1000 at age 85+. The 4 main prevalent pathologies among MHS 
population aged 40 or above were open angle glaucoma, pre or borderline 
glaucoma, unspecified glaucoma, and pseudo exfoliation with prevalence rates 
of 2%, 1.4%, 0.9% and 0.2%, respectively. A total of 11,512 incident glaucoma 
patients, who were diagnosed between 2003 and 2010 were identified, with an 
average incidence of 2.5 per 1000 among 40+ year old members. Overall, 1.5% of 
the study patients have undergone glaucoma surgery, 3% were blind and 41% 
were diagnosed with cataract. CONCLUSIONS: The current study demonstrates 
the potential use of automated medical databases to estimate the burden of 
glaucoma and its complications. The increased comorbidity and mortality 
among these patients has important implication for health authorities for 
prevention and delivery of health-care services.  
 
PSS4  
PREVALENCE AND INCIDENCE OF PATHOLOGIC MYOPIA AND RETINAL 
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OBJECTIVES: The epidemiology of pathologic myopia (PM), an important cause of 
visual impairment worldwide, is poorly understood. This study analyzed data 
from a large US claims database to estimate the prevalence and incidence of PM 
and PM + retinal neovascularization (RNV). METHODS: Data were drawn from 
the MarketScan® Commercial Claims and Encounters database and Medicare 
Supplemental and Coordination of Benefits in the USA. ICD9 diagnostic codes for 
PM (360.21) and both PM + RNV (362.16) were used to identify cases; use of the 
diagnostic code on at least one occasion was required. A 1-year disease-free 
period was required for a diagnosis to be considered an incident case. RESULTS: 
MarketScan covered 45,226,794 patients in 2011; 43,581 and 1,781prevalent cases 
of PM and PM + RNV were identified, representing a prevalence of 9.64 (95% CI: 
9.55–9.73) and 0.39 (95% CI: 0.38–0.41) per 10,000 population, respectively. 
Incidence per 10,000 persons in 2011 was 2.75 (95% CI: 2.70–2.80) for PM and 0.09 
(95% CI: 0.08–0.10) for PM + RNV. Subjects with incident PM had a mean age of 
47.9±18.5 years, 46.5% were under 50 years old, and 62.3% were females, whereas 
subjects with PM + RNV had a mean age of 55.1±14.5, 30.3% were younger than 
50 years old, and 71.1% were females. CONCLUSIONS: Prevalence and incidence 
estimates of PM among the commercially insured US population in 2011 were 
approximately 9.6 and 2.7 per 10,000 persons, respectively. PM+RNV represents 
approximately 3−4% of patients with PM. Using only one diagnostic code to 
identify cases may overestimate prevalence and incidence as there is potential 
to include some diagnoses that would later be ruled out as true cases. Both PM 
and PM+RNV are often diagnosed in individuals younger than 50 years of age and 
the majority of patients are female.  
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OBJECTIVES: Anti-VEGF therapy with ranibizumab (RBZ) dosed monthly 
improves visual acuity over time in patients with neovascular (“wet”) age-related 
macular degeneration (wAMD). In two identical phase 3 trials, IAI dosed 2mg 
every 2 months, following 3 initial monthly doses (2Q8) demonstrated clinically 
equivalent efficacy and a similar safety profile to RBZ 0.5mg dosed monthly 
(RQ4). We assessed the budgetary impact of adding IAI 2Q8 to a formulary of a 
hypothetical one million member US health plan. METHODS: A Markov model 
characterized treatment with IAI 2Q8 and RQ4 over time. Health states were 
based on visual acuity in the better-seeing eye. Efficacy and cost estimates came 
from clinical trial data and published literature. The model calculated direct 
medical costs, including costs of drug, administration, monitoring, visual 
impairment, and adverse events. Ten percent of patients were assumed to be 
treated in both eyes. We calculated budgetary impact by comparing estimated 
costs over three years from current (100% RBZ market share) through future 
scenarios (IAI market share: Year 1, 22%; Year 2, 42%; Year 3, 51%). Model 
outcomes include total costs over three years in current and future scenarios, 
net costs, and cost per-member per-month (PMPM). RESULTS: In a one million 
member plan, 2,800 were newly treated for wAMD. Total budget was $79.2 
million in Year 1, $147.9 million in Year 2 and $152.4 million in Year 3 in the 
current scenario, and $71.9 million, $126.5, and $121.2 million in Years 1, 2 and 3 
in the future scenario. Net budget impact ranged from $-7.3 million in Year 1 to 
$-31.2 million in Year 3, or $0.61, $1.78, and $2.60 PMPM savings in Years 1, 2, and 
3. CONCLUSIONS: Adding IAI 2Q8 to a US formulary saves money in the first 
three years, primarily due to reduced injection frequency compared to RQ4.  
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COST ANALYSIS OF PARS PLANA VITRECTOMY FOR THE TREATMENT OF 
SYMPTOMATIC VITREOMACULAR ADHESION: A BOTTOM-UP COSTING 
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The direct cost to the NHS of pars plana vitrectomy (PPV) is unknown since a 
bottom-up costing exercise has not been undertaken. Health care resource group 
(HRG) costing relies on a top-down approach. OBJECTIVES: To quantify the direct 
cost of PPV for vitreomacular traction (VMT), epiretinal membrane (ERM) and 
macular hole (MH). METHODS: Each of five NHS vitreoretinal units recorded the 
indication for surgery and all procedure elements for a minimum of 30 
consecutive PPVs, to include at least 10 cases of VMT, ERM, or MH. In-surgery 
bottom-up costing was undertaken by prospectively recording all consumables, 
equipment and staff salaries associated with surgery, between March and 
September 2012. Out-of-surgery costs, namely before and after surgery between 
admission and discharge, were estimated based on accounting costs recorded in 
one site. RESULTS: Of 151 PPVs, 57 were for MH (16.6%), ERM (15.2%), or VMT 
(4%). The average surgical time was 1.22 hours [range 0.96-1.38], corresponding to 
an average staff cost of £280.40 [£184.90-£376.70]. The average cost of 
consumables was £534.60 [£406.55-£688.85], and of equipment £87.75 [£28.10-
£139.15]. The average direct cost of PPV in theatre was £901.10 [£671.00-£1185.55]. 
Average out-of-surgery costs were estimated at £325.35, including nursing staff, 
extra consumables and hospitalisation costs. This resulted in a total cost of 
£1673.80 [£1496.40-£1863.30], including 30% overheads. This cost estimate is 
considered an under-estimate because of lack of available data on departmental-
level general costs, medical and anaesthetic staff costs incurred out-of-surgery. 
The average effective HRG tariff reimbursed was £1701.20. CONCLUSIONS: These 
figures indicate that the real cost incurred is likely to be higher than the 
reimbursed tariff, but it may be cost-effective for NHS hospitals to undertake 
additional PPVs for VMT, ERM and MH, if they can amortise existing 
infrastructure with a sufficient number of interventions to benefit from 
economies of scale.  
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THE COST AND THE EDUCATIONAL IMPACT OF COCHLEAR IMPLANTATION IN 
CHILDREN OVER A FOUR YEAR PERIOD IN FRANCE  
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OBJECTIVES: Cochlear implants (CI) are electronic devices introduced surgically 
into the inner ear. This is the only medical treatment for profound total 
deafness. CI is particularly useful in children because they can have an impact 
on the children education. The aim of this study is to assess the cost and the 
educational impact of CI in French implanted children over a four year period 
METHODS: 268 profoundly deaf children were recruited and implanted between 
September 2002 and December 2004 in 16 specialized French hospitals. The 
educational impact was assessed in children aged less than 2 years and aged 
over 2 years using the educational rate evolution and the type of integrated 
